| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 34,319 | 56,095 | 52,031 | 63,249 |
| Partner share and other third-party costs | 14,597 | 24,395 | 22,001 | 27,103 |
| Delivery costs | 2,581 | 5,810 | 5,730 | 6,883 |
| Sales and marketing expense | 6,761 | 7,524 | 7,865 | 11,335 |
| Research and development expense | 6,430 | 7,965 | 8,799 | 11,295 |
| General and administrative expense | 8,281 | 9,730 | 10,854 | 12,905 |
| Acquisition, integration and divestiture costs | NaN | NaN | 0 | 0 |
| Acquisition, integration and divestiture costs (benefits) | NaN | 140* | NaN | NaN |
| Change in contingent consideration | 0 | 0 | 0 | 42 |
| Impairment of goodwill and intangible assets | NaN | -10,799* | 58,843 | NaN |
| Loss (gain) on disposition of business | NaN | -11,219* | NaN | NaN |
| Gain on divestiture | 0 | NaN | -320 | -200 |
| Depreciation and amortization expense | 3,943 | 6,205 | 6,473 | 6,275 |
| Total costs and expenses | 42,593 | 62,189 | 120,885 | 76,038 |
| Operating loss | -8,274 | -6,094 | -68,854 | -12,789 |
| Interest expense, net | -2,533 | -2,139* | -2,007 | -1,943 |
| Loss on investment | -1,285 | NaN | NaN | NaN |
| Foreign currency (gain) loss | -1,706 | -17 | -1,812 | 5,449 |
| Gain on debt extinguishment | NaN | 0* | 0 | 0 |
| Total other income (expense) | -5,524 | -2,156 | -3,819 | 3,506 |
| Loss before income taxes from continuing operations | -13,798 | -8,250 | -72,673 | -9,283 |
| Income tax benefit | 0 | 0 | NaN | NaN |
| Loss from continuing operations | -13,798 | NaN | NaN | NaN |
| Income (loss) from discontinued operations | 9,318 | NaN | NaN | NaN |
| Net loss | -4,480 | -8,250 | -72,673 | -9,283 |
| Basic EPS | NaN | -0.152 | -1.36 | -0.18 |
| Diluted EPS | NaN | -0.152 | -1.36 | -0.18 |
| Basic Average Shares | 54,896,000 | 54,350,000 | 53,493,000 | 52,750,000 |
| Diluted Average Shares | 54,896,000 | 54,350,000 | 53,493,000 | 52,750,000 |
Cardlytics, Inc. (CDLX)
Cardlytics, Inc. (CDLX)